ClinicalTrials.gg
RecruitingNCT07030803HAV-O-TENSUpdated Nov 18, 2025

Comparative Study of the Efficacy of Treatment of Idiopathic Overactive Bladder (OAB) in Children: Oxybutynine vs. Transcutaneous Neurostimulation

An interventional study of Oxybutynin and medical device Urostim in Overactive Bladder (OAB), Transcutaneous Neurostimulation and Posterior Tibial Nerve Stimulation, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
6 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Urinary Bladder, Overactive with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Urinary Bladder, Overactive · France.

Planned enrollment
27th of 40
124 · median 267
Started
2025
with 1 other
No phase
11 of 53
5 open now
Registered
52nd of 53
by date

Among the 53 studies in Urinary Bladder, Overactive with a site in France, this one is the 27th largest by planned enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 52nd registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

6 of the 53 studies in Urinary Bladder, Overactive with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 6 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Urinary Bladder, Overactive with a site in France, or all of them as a file.
02

Study summary

The absence of infectious, urological and neurological causes defines the idiopathic character of overactive bladder (OAB). Although a progressive approach starting with behavioural therapy (urotherapy) is recommended, anticholinergic agents remain the mainstay of medical treatment of overactive bladder (OAB) in children. Bladder neuromodulation is also used but no study with sufficient evidence has assessed its effectiveness and tolerance compared to the reference treatment. The purpose of HAV-O-TENS is to demonstrate the non-inferiority of treating idiopathic overactive bladder (OAB) in children using posterior tibial nerve stimulation (PTNS) compared to the reference treatment with oxybutynin after three months of treatment.

Before inclusion, patients will receive instructions for urotherapy and a treatment plan. After confirming the diagnosis and obtaining informed consent, patients will be randomly assigned to either oxybutynin or PTNS (posterior tibial nerve stimulation) treatment, and their effectiveness, tolerance, and adherence will be monitored.

03

Conditions studied

  • Overactive Bladder (OAB)
  • Transcutaneous Neurostimulation
  • Posterior Tibial Nerve Stimulation

Keywords

  • Overactive Bladder
  • transcutaneous neurostimulation
  • posterior tibial nerve stimulation
04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 6 to 16 years
  • Showing signs of OAB (pollakiuria (> 8 micturitions/d and/or urgenturia(>x2/week) and/or daytime urine leakage (1/d) and/or nocturia x2/night)
  • No treatment for more than 3 months
  • Urotherapy rules followed for at least 1 month
  • Beneficiary of a social security plan
  • Signature of consent by parents/legal guardian(s) and child's agreement

Exclusion criteria

Exclusion Criteria:

  • Neurological cause of bladder dysfunction,
  • History of pelvic surgery,
  • Significant post-micturition residual (> 10% of micturition),
  • Recurrent urinary tract infections (> 3) in the 6 months prior to inclusion or urinary tract infection at inclusion.
  • Pregnant or breast-feeding adolescents
  • Severe constipation resistant to treatment (Rome IV),
  • to oxybutynin
  • Contraindication to the use of TENS (Urostim)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Active comparator
    oxybutynin

    Other: Oxybutynin

  • Experimental
    TENS

    Device: medical device Urostim

Interventions

  • OtherOxybutynin

    oxybutynin

  • Devicemedical device Urostim

    medical device used to deliver posterior tibial nerve stimulation (PTNS)

06

What researchers measure

Primary outcomes

  1. Variation of DVISS score between PTNS treatment group and oxybutynin group

    DVISS score is : Dysfunctional Voiding and Incontinence Symptoms Score (DVISS) Questionnaire. The DVISS is a 13-item instrument that includes 1 QOL question. The first 5 questions are scored using an ordinal scale with the remainder in binary format. The DVISS scores are based on the estimated odds ratio (OR) for each question between cases and controls. For example, a score of 1 is given if the item's OR is between 2 and 10, and a score of 5 is given if the OR is greater than 50. The total score can range from 0 to 35 with a cutoff score of 8.5 having 90% sensitivity and specificity at detecting BBD.

    Time frame: at 3 months

Secondary outcomes

  1. variation of treatment duration between both groups

    Time frame: at 6 months

  2. variation of time to treatment efficacy between both groups

    Time frame: at 6 months

  3. variation of tolerance between both groups

    Time frame: at 3 months

  4. variation of tolerance between both groups

    Time frame: at 6 months

  5. variation of compliance between both groups

    variation of compliance between both groups

    Time frame: at 3 months

  6. variation of compliance between both groups

    variation of compliance between both groups

    Time frame: at 6 months

  7. variation of long-term efficacy between both groups

    Time frame: at 12 months

  8. variation of long-term efficacy between both groups

    Time frame: at 18 months

  9. variation of long-term efficacy of AOB frequency between both groups

    Long term efficacy of OAB frequency is measured with DVISS score. The DVISS is a 13-item instrument that includes 1 QOL question. The first 5 questions are scored using an ordinal scale with the remainder in binary format. The DVISS scores are based on the estimated odds ratio (OR) for each question between cases and controls. For example, a score of 1 is given if the item's OR is between 2 and 10, and a score of 5 is given if the OR is greater than 50. The total score can range from 0 to 35 with a cutoff score of 8.5 having 90% sensitivity and specificity at detecting BBD.

    Time frame: at 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2029, 40 months after the start.

Of 135 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 40 months is above that.

Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
Jun 22, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07030803
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Nov 5, 2025
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 18, 2025

Study contacts

Elodie Haraux, Pr
Contact
Haraux.elodie@chu-amiens.fr
33+322836787

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion